Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -19.44% |
| Q2 2025 | -21.56% |
| Q1 2025 | -52.82% |
| Q4 2024 | 7.34% |
| Q3 2024 | 13.23% |
| Q2 2024 | 36.89% |
| Q1 2024 | 4.68% |
| Q4 2023 | 1.00% |
| Q3 2023 | 72.38% |
| Q2 2023 | 5.91% |
| Q1 2023 | -40.49% |
| Q4 2022 | 105.01% |
| Q3 2022 | -9.95% |
| Q2 2022 | -51.84% |
| Q1 2022 | -2.04% |
| Q4 2021 | 20.01% |
| Q3 2021 | -0.17% |
| Q2 2021 | -21.42% |
| Q1 2021 | 39.37% |
| Q4 2020 | -25.42% |
| Q3 2020 | 13.09% |
| Q2 2020 | -24.13% |
| Q1 2020 | -25.04% |
| Q4 2019 | 48.84% |
| Q3 2019 | 53.79% |
| Q2 2019 | 26.24% |
| Q1 2019 | 4.37% |
| Q4 2018 | 7.90% |
| Q3 2018 | 14.71% |
| Q2 2018 | -17.38% |
| Q1 2018 | -28.62% |
| Q4 2017 | 80.94% |
| Q3 2017 | -7.34% |
| Q2 2017 | 24.30% |
| Q1 2017 | -13.40% |
| Q4 2016 | 15.35% |
| Q3 2016 | 0.00% |